Thymagen vs Vilon: what the evidence actually supports

A reader on one of the longevity forums asked me last month why Thymagen keeps showing up next to Vilon in the same breath, as if they were interchangeable. They are not. Short answer: Thymagen vs Vilon comes down to one thing more than any other, Vilon has actual human data behind it and Thymagen does not, and that gap should drive which one you reach for.

Both come out of the same Russian research tradition, the Khavinson school of short bioregulator peptides, tiny two-amino-acid molecules that are theorized to slip into cell nuclei and nudge gene expression toward a younger pattern. I find that mechanism genuinely interesting, and I've spent a fair amount of time going through the primary literature on this peptide family because so little of it gets translated into English with any rigor. What I keep landing on is that these two peptides, despite sharing a research lineage, are not equally supported, and treating them as a matched pair does a disservice to anyone trying to make an actual decision.

Evidence quality: this is where they split

Thymagen's file is thin. The best support for its underlying mechanism comes from in-vitro work showing that short Khavinson peptides can penetrate cell nuclei and interact with DNA, a mechanism study. Beyond that, there's an older study on cAMP and phosphodiesterase activity in spleen lymphocytes that included Thymagen alongside two other peptides during an anaphylaxis model. That's animal and in-vitro territory, and it's genuinely the extent of what's published on Thymagen by name.

Vilon is a different story. It shares the same nuclear-penetration and gene-expression mechanism work at the in-vitro level, but it also has actual Russian human cohorts behind it. A 2007 study found improved coagulation and immune markers along with reduced insulin requirements in elderly diabetics, a related 2006 paper found reduced DIC syndrome in type-1 diabetes patients, and a 2005 case series reported improved survival and fewer complications in elderly stage-III colorectal cancer patients given Vilon. None of these are large randomized trials by Western standards, and none of them have been replicated outside that research group as far as I can find, which matters. But they are human data, in patients with real diagnoses, and Thymagen simply does not have an equivalent.

Vilon also has more recent in-vitro work behind it, including epigenetic changes in aging human mesenchymal stem cells where Vilon increased SIRT1 and reduced PARP1/PARP2 expression, work tied to the same selective heterochromatin decondensation findings that show up across the Khavinson family. I see this pattern a lot with this peptide class: the mechanism story is consistent and reasonably well built out, while the human clinical layer varies enormously from one family member to the next. Vilon happens to be the one with the deepest human layer after thymalin itself.

Cost and sourcing: no real difference

I don't see a meaningful price gap between the two. Both are simple dipeptides synthesized by a small pool of suppliers, and pricing in this category tracks purity and batch testing far more than which specific peptide you're buying. The bigger issue with both Thymagen and Vilon is that Khavinson-family peptides are, in my experience watching this market, the most counterfeited and mislabeled category out there. If you go this route, get a third-party certificate of analysis and check it against the batch number on the vial.

Heads up: OHM has an affiliate relationship with the vendors linked on this site, so we earn a commission if you buy through one of these links. It costs you nothing extra and it does not change which peptide the evidence supports.

Side-effect load: both are quiet

Neither peptide has a documented pattern of serious adverse events in the Russian literature. What gets reported is mild and unremarkable, occasional injection-site irritation and a transient headache early in a cycle. I've talked to people who've run both, and the reports are consistently boring in the good sense, nothing dramatic, nothing that reads as a red flag. That's a real point in favor of both compounds if what you're weighing is risk tolerance rather than proof of benefit.

Who each one actually suits

If you want a thymic or immune-support peptide and human data matters to you, Vilon is the more defensible pick between these two. Its cohort studies target real conditions (diabetes, coagulation problems, post-surgical cancer outcomes), even if they're small and unreplicated outside Russia. If you're drawn to Thymagen specifically because it's positioned as the more distilled, more targeted successor to thymalin, understand you're betting on family-wide mechanism plausibility.

If what you actually want is a well-evidenced Western thymic immune peptide with an active research-vendor market, thymosin alpha-1 has a stronger claim on that territory than either Thymagen or Vilon. These two are worth knowing about for their depth of history and their place in the Khavinson research tradition, and Vilon in particular has more going for it than it usually gets credit for. But go in knowing which one you're actually picking and why.

Dosing and cycling

There's no Western dose-finding trial for either peptide, so what follows is the real-world protocol the Khavinson-community has converged on. The pattern for both Thymagen and Vilon is a short course of 10 to 20 consecutive days, repeated 2 to 3 times a year, with subcutaneous dosing in the range of 100 to 200 mcg per day during that window. Some suppliers in the Russian retail market also sell these as oral capsules or sublingual drops, though the community data behind those routes is thinner than for the injectable form.

Now the part my lawyer makes me say, and he is right: The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

If you want to see how each peptide's full profile lays out, including the mechanism detail and the sourcing notes, the Thymagen and Vilon pages have the complete breakdown. And if you're building out a broader stack and want to think through what else pairs well with a thymic-support peptide, the fatigue and energy breakdown on 5-Amino-1MQ is a useful read on how I approach evaluating thin-evidence compounds generally.

Thanks for reading! In health, Rick Gold